Portal de investigação
Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled
Data de publicação:
Data Ahead of Print:
Autores da FMUP
Participantes de fora da FMUP
- Zannad, F
- Butler, J
- Filipattos, G
- Ritter, I
- Schuler, E
- Kraus, BJ
- Pocock, SJ
- Anker, SD
- Packer, M
Unidades de investigação
Abstract
Aims Hyperkalaemia frequently leads to interruption and discontinuation of neurohormonal antagonists, which may worsen heart failure prognosis. Some studies suggested that sodium-glucose cotransporter 2 inhibitors reduce hyperkalaemia, an effect that may have important clinical implications. This analysis evaluates the effect of empagliflozin on the occurrence of hyper- and hypokalaemia in HF. Methods and results EMPEROR-Pooled (i.e. EMPEROR-Reduced and EMPEROR-Preserved combined) included 9583 patients with available serum potassium levels at baseline (98.6% of the total EMPEROR-Pooled population, n = 9718). Hyperkalaemia was identified by investigators' reports of adverse events, and by a laboratory serum potassium value above 5.5 mmol/L and 6.0 mmol/L. The main outcome was a composite of investigator-reported hyperkalaemia or initiation of potassium binders. Patients with high potassium at baseline were more frequently diagnosed with diabetes and ischaemic HF aetiology and had lower left ventricular ejection fraction and estimated glomerular filtration rate but were more frequently treated with sacubitril/valsartan or mineralocorticoid receptor antagonists. Empagliflozin (compared with placebo) reduced the composite of investigator-reported hyperkalaemia or initiation of potassium binders [6.5% vs. 7.7%, hazard ratio (HR) 0.82, 95% confidence interval (CI) 0.71-0.95, P = 0.01]. Empagliflozin reduced hyperkalaemia rates regardless of the definition used (serum potassium >5.5 mmol/l: 8.6% vs. 9.9%, HR 0.85, 95% CI 0.74-0.97, P = 0.017; serum potassium >6.0 mmol/l: 1.9% vs. 2.9%, HR 0.62, 95% CI 0.48-0.81, P < 0.001). The incidence of hypokalaemia (investigator-reported or serum potassium <3.0 mmol/l) was not significantly increased with empagliflozin. Conclusions Empagliflozin reduced the incidence of hyperkalaemia without significant increase in hypokalaemia.
Dados da publicação
- ISSN/ISSNe:
- 1522-9645, 0195-668X
- Tipo:
- Article
- Páginas:
- 2984-2993
- Link para outro recurso:
- www.scopus.com
European Heart Journal Oxford University Press
Citações Recebidas na Web of Science: 23
Citações Recebidas na Scopus: 48
Documentos
- Não há documentos
Filiações
Keywords
- Potassium; Hyperkalaemia; Heart failure; Empagliflozin
Financiamento
Proyectos asociados
Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684
Investigador Principal: João Pedro Melo Marques Pinho Ferreira
Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022
Citar a publicação
Ferreira JP,Zannad F,Butler J,Filipattos G,Ritter I,Schuler E,Kraus BJ,Pocock SJ,Anker SD,Packer M. Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled. Eur. Heart J. 2022. 43. (31):p. 2984-2993. IF:39,300. (1).
